Quantcast
42.6 F
Newark, Delaware
Friday, November 24, 2017

AG’s office retains law firms to see if opioid, makers, wholesalers should be...

Attorney General Matt Denn announced that the Delaware Department of Justice retained a national group of attorneys and experts to investigate and, if appropriate, file suit against opioid manufacturers, opioid distributors, and other entities...

AstraZeneca gets fast-track FDA approval process for promising blood cancer drug

AstraZeneca and its hematology research and development unit  Acerta Pharma, announced that the  Food and Drug Administration (FDA) was granted accelerated approval to Calquence (acalabrutinib), a drug used to fight an aggressive form of blood cancer. The...

Shortened sign-up period under way for Health Insurance Marketplace program

Sign-up  gets underway today for the Delaware’s Health Insurance Marketplace. The sign-up period has been cut from 12 to six weeks under a series of moves by the Trump Administration that also include sharply cutting...

Christiana Care to close and remodel center near Wilmington

Christiana Care Health System is making improvements to its Eugene du Pont Preventive Medicine & Rehabilitation Institute (PMRI) near Wilmington. Renovations at PMRI will begin in November 2017 and are expected to be complete in late...

Incyte reports strong revenue gains in third quarter report

Incyte Corporation reported 38 percent year-on-year growth in product  revenue in its third quarter earnings report. The company said the gains were driven by increased sales of Jakafi  (ruxolitinib) in the U.S. and Iclusig  (ponatinib)...

Attorneys general widen scope of generic drug price-fixing lawsuit

The Delaware Attorney General and other Attorneys General have  expanded the scope of a lawsuit against generic drug manufacturers alleging illegal price-fixing agreements.   The lawsuit, which now also names two individual executives of the defendant...

Incyte, AstraZeneca announce trial of drug combination

 Incyte Corporation   and MedImmune,  AstraZeneca’s  global biologics research and development arm, announced the expansion of their clinical collaboration on a combination of drugs that would treat a type of lung cancer. Incyte is based near...

Delaware moves into the top 10 in the rate of sexually transmitted diseases

Delaware’s rate of sexually transmitted disease rose sharply last year. The report from BackgroundCheck.org  showed the First State moving up to ninth in a ranking of the 50 states, up five places from a year...

Incyte, Microgenics strike deal, valued at up to $900 million, for...

Incyte Corporation   and     MacroGenics, Inc.   entered into a global collaboration and license agreement for MacroGenics’ MGA012. MGA012 is  a  monoclonal antibody that inhibits programmed cell death protein 1 that shows potential in cancer treatment. Incyte, which...

New diabetes formulation from AstraZeneca gets FDA OK

AstraZeneca announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise. The new formulation of Bydureon is an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more...
Advertisement